



REFERENCES

1. Abdel Fattah M, Abdel Ghany E, Adel A, Mosallam D, Kamal S.
“Glucose-6-phosphate dehydrogenase and red cell pyruvate kinase deficiency in neonatal jaundice cases in Egypt”. [pediatr Hematol Oncol 2010 May; 27(4):262-71].
2. Abrams ME, Meredith KS, Kinnard P, Clark RH. “Hydrops fetalis: a retrospective review of cases reported to a large national database and identification of risk factors associated with death”: Pediatrics. Jul 2007; 120(1):84-9].
3. Agency for Healthcare Research and Quality.” Management of neonatal hyperbilirubinemia”. Rockville, Md. United States Department of Health and Human Services, Agency for Healthcare Research and Quality; [2003, Pediatrics Vol. 114 No.1 July 1.2004 PP.e130-e153].
4. Ahlfors CE, Wennberg RP. “Bilirubin-albumin binding and neonatal jaundice”. Semin Perinatol. Oct 2004; 28(5):334-9.
5. Ahlfors CE. “Predicting bilirubin neurotoxicity in jaundiced newborns”: Curr Opin Pediatr. Apr 2010; 22(2):129-33.
6. Aizawa S, Kohdera U, Hiramoto M, et al. “Ineffective erythropoiesis in the spleen of a patient with pyruvate kinase deficiency”: [Am J Hematol. Sep 2003; 74(1):68-72].
7. Alcock GS, Liley H. Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database of Syst Rev. 2002; 3



REFERENCES

8. Alexandra Brito M, Silva RF, Brites D. “Bilirubin toxicity to human erythrocytes”: a review. [Clin Chim Acta. Dec 2006; 374(1-2):46-56].
9. AlSaedi S. A. “Rebound hyperbilirubinemia in term infants after phototherapy”. [Saudi Med J 2002. 23:1394–1397].
10. American Academy of Pediatrics, Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia Practice parameter: “Management of hyperbilirubinemia in the healthy term newborn”. [Pediatrics 1994. 94:558–565].
11. American College of Obstetricians and Gynecologists, American Academy of Pediatrics. “Neonatal Encephalopathy and Cerebral Palsy: Defining the Pathogenesis and Pathophysiology”. [NeoReviews 2003; 4:e33].
12. American Academy of Pediatrics. Red Book 2003. 26th ed. 2003; 117-123, 237-43, 561-73, 584-91
13. American Academy of Pediatrics. “Sepsis guidelines”. [Red Book 2003. 26th ed. 2003; 117-123, 237-43, 561-73, 584-9].
14. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation: Pediatrics. Jul 2004; 114(1):297-316. American Academy of Pediatrics. “Committee on Fetus and Newborn”. Hospitals stay for healthy term newborns. *Pediatrics*. 2010; 125: 405.



REFERENCES

15. Atkinson LR, Escobar GJ, Takyama, JI, Newman TB. "Phototherapy use in jaundiced newborns in a large managed care organization: do clinicians adhere to the guideline?" *Pediatrics*. 2003; 111:e555.
16. Bakkeheim E, Bergerud U, Schmidt-Melbye AC, et al. "Maternal IgG anti-A and anti-B titres predict outcome in ABO-incompatibility in the neonate": [Acta Paediatr. Dec 2009; 98(12):1896-901].
17. Bancroft JD, Kreamer B, Gourley GR. "Gilbert syndrome accelerates development of neonatal jaundice": *J Pediatr*. Apr 1998; 132(4):656-60].
18. Bansal A, Jain S, Parmar VR. "Bilirubin rebound after intensive phototherapy for neonatal jaundice". *Indian Pediatr* 2010 Jul 7; 47(7):607-9.
19. Baranano DE, Rao M, Ferris CD, Snyder SH (). "Biliverdin reductase: a major physiologic cytoprotectant". *Proc. Natl. Acad. Sci. U.S.A* 2002; 99 (25): 16093–8.
20. Bernhard V. "Bilirubin, metabolism and jaundice". In: Brandt LJ, ed. *Clinical Practice of Gastroenterology*. New York, NY: Churchill Livingstone; 1999.
21. Bertini G, Dani C, Trochin M, Rubaltelli F. "Is breastfeeding really favoring early neonatal jaundice?" [*Pediatrics*. 2001; 107 (3)].
22. Beutler E. "Glucose-6-phosphate dehydrogenase deficiency: a historical perspective": *Blood*. Jan 1 2008; 111(1):16-24.



REFERENCES

23. Bhutani VK, Johnson L, Sivieri EM. "Predictive ability of a predischARGE hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns" *Pediatrics*. Jan 1999; 103(1):6-14.
24. Bhutani VK, Johnson LH, Maisels MJ, et al. "Kernicterus: epidemiological strategies for its prevention through systems-based approaches": *J Perinatol*. 2004; 24:650-62.
25. Bhutani VK, Donn SM, Johnson LH. "Risk management of severe neonatal hyperbilirubinemia to prevent kernicterus:.. [*Clin Perinatol*. 2005; 32 (1):125 - 39, vii].
26. Bhutani VK, Johnson L. "Kernicterus in the 21st century: frequently asked questions". *J Perinatol*. Feb 2009; 29 Suppl 1:S20-4.
27. Bossuyt X, Blanckaert N. "Carrier-mediated transport of uridine diphosphoglucuronic acid across the endoplasmic reticulum membrane is a prerequisite for UDP-glucuronosyltransferase activity in rat liver". *Biochem J* (1997); 323, 645–648.
28. Brites D, Fernandes A, Falcão AS, Gordo AC, Silva RF, Brito MA. "Biological risks for neurological abnormalities associated with hyperbilirubinemia". *J Perinatol*. Feb 2009; 29 Suppl 1:S8-13.
29. British Paediatric Surveillance Unit. "Surveillance of severe hyperbilirubinaemia in the newborn commenced the May". *BPSU Quarterly Bulletin*. 2003; 11(2):2.



REFERENCES

- 30.Canadian Paediatric Society. Position Statement (FN 2007-02). “Guidelines for detection, management and prevention of hyperbilirubinaemia in term and late preterm newborn infants (35 or more weeks’ gestation”). *Pediatr Child Health* 2007; 12:1B-12B.
- 31.Carl L, Berg JM. “Bilirubin metabolism and the pathophysiology of jaundice”. In: Schiff ER, Gollan JL, eds. *Schiff's: “Disease of the Liver”*; 1999. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins.
- 32.Cartwright D, Ingliss GDT, Davies MW. “Jaundice”. In: Davies MW, Cartwright DW, Ingliss GDT, editors. [Pocket Notes on Neonatology. 2nd ed. Australia: Churchill Livingstone; 2008. p. 97-103].
- 33.Castro O.” Management of sickle cell disease: recent advances and controversies”: [Br J Haematol. Oct 1999; 107(1):2-11].
- 34.Chang PF, Lin YC, Liu K, Yeh SJ, Ni YH. “Prolonged unconjugated hyperbilirubinemia in breast-fed male infants with a mutation of uridine diphosphate-glucuronosyl transferase”: *J Pediatr*. Aug 13 2009; 155:860-3. 109
- 35.Chen TS, Chen PS (1984).” Understanding the Liver”. A History. Westport, CT: Greenwood Press, p. 99.
- 36.Chen ZP, Hetzel BS. “Cretinism revisited”: *Best Pract Res Clin Endocrinol Metab*. Feb 2010; 24(1):39-50.
- 37.Christensen RD, Henry E. “Hereditary spherocytosis in neonates with hyperbilirubinemia”: [*Pediatrics*. Jan 2010; 125(1):120].



REFERENCES

38. Clementi M, 2007 Di Gianantonio E, Fabris L, Forabosco P, Strazzabosco M, Tenconi R. "Inheritance of hyperbilirubinemia: evidence for a major autosomal recessive gene": *Dig Liver Dis.* Apr; 39(4):351-5.
39. Colletti JE, Kothori S, Jackson DM, Kilgore KP, Barringer K. "An emergency medicine approach to neonatal hyperbilirubinemia": *Emerg Med Clin North Am.* Nov 2007; 25(4):1117-35, vii.
40. Cremer and coworkers Cremer RJ, Perryman PW, Richards DH. "Influence of light on the hyperbilirubinemia of infant"s. [1958; 1094-1097].
41. Cui Y, Konig J, Leier I et al. "Hepatic uptake of bilirubin and its conjugates by the human organic anion-transporting polypeptide 2(symbol SLC21A6)". *J Biol Chem.* (2000); 276, 9626–9630 Rockville (MD). "Screening for Rh(D) incompatibility". Recommendation statement: Agency for Healthcare Research and Quality (AHRQ). 2004.
42. Daniel S. Bowerman, Harry J. Morgan. "Management of hyperbilirubinemia": [Expert Opin Pharmacother. 2003; 4(11):1939-4].
43. De Carvalho M, De Carvalho D, Trzmielina S, et al. "Intensified phototherapy using daylight fluorescent lamps". [Acta Paediatr. Jul 1999; 88(7):768-71].
44. Delange F. "Neonatal thyroid screening as a monitoring tool for the control of iodine deficiency": *Acta Paediatr Suppl.* Dec 1999; 88(432):21-4.



REFERENCES

45. Del Vecchio M T, Benstock M A, Sundel E R. "Bilirubin rebound. [J Pediatr]; 1999. 135:531–532].
46. Demott K, Bick D, Norman R, Ritchie G, Turnbull N, Adams C, et al. "Clinical Guidelines and Evidence Review For Postnatal Care: Routine Post Natal Care Of Recently Delivered Women And Their Babies". [National Collaborating Centre for Primary Care and Royal College of General Practitioners. 2006; [290-296].
47. Dennerly PA, Seidman DS, Stevenson DK. "Neonatal hyperbilirubinemia": NEJM. 2001; 344:581-90.
48. Diez A, Gilsanz F, Martinez J, et al. "Life-threatening nonspherocytic hemolytic anemia in a patient with a null mutation in the PKLR gene and no compensatory PKM gene expression": [Blood. Sep 1 2005; 106(5):1851-6].
49. Donneborg ML, Knudsen KB, Ebbesen F. "Effect of infants' position on serum bilirubin level during conventional phototherapy". Acta Paediatr. 2010 Aug; 99(8):1131-4. Epub 2010 Jun 2.
50. Ebbesen F. "Recurrence of kernicterus in term and near-term infants in Denmark". [Acta Paediatr. Oct 2000; 89(10):1213-7].
51. Ebbesen F, Andersson C, Verder H, Grytter C, Pedersen-Bjergaard L, Petersen JR, et al. "Extreme hyperbilirubinaemia in term and near-term infants in Denmark". [Acta Paediatr. Jan 2005; 94(1):59-64].



REFERENCES

52. Elbirt KK, Bonkovsky HL “Heme oxygenase: recent advances in understanding its regulation and role”: Proc Assoc Am Phys; 1999 :111,438–447.
53. E.A. Letsky; I. Leck, J.M. Bowman (2000). "Chapter 12: Rhesus and other haemolytic diseases". Antenatal & neonatal screening (Second Ed.). Oxford University Press.
54. Elizabeth Shaw, Danielle Grenier, “Prevention of kernicterus”. *Pediatr Child Health* 2007; 12:1B-12B]
55. Erdeve O, Tiras U, Dallar Y. “Rebound bilirubin measurement is not required for hyperbilirubinemia regardless of the background attributes of the newborns. [J Trop Pediatr 2004. 505].
56. Falcão AS, Silva RF, Fernandes A, Brito MA, Brites D. “Influence of hypoxia and ischemia preconditioning on bilirubin damage to astrocytes”: *Brain Res.* May 29 2007; 1149:191-9].
57. Gartner LM. “Neonatal jaundice”. [Pediatr Rev. Nov 1994; 15(11):422-32].
58. Gartner. “Jaundice and breastfeeding”: *Pediatr Clin North Am* 2001;48(2):389-99
59. Ghosh SS, Sappal BS, Ganjam VK et al. “Homodimerization of human bilirubin-uridine-diphospho-glucuronosyltransferase-1 (UGT1A1) and its functional implications”. *J Biol Chem* (2001) 276,42108–42115.



REFERENCES

60. Gieger, A. S., Rice, A.C., Shapiro, S. M., “Minocycline blocks acute bilirubin induced neurological dysfunction in jaundiced Gunn rats”. *Neonatology* 92:219-226, 2007.
61. Gourley GR, Li Z, Kreamer BL, Kosorok MR. “A controlled, randomized, double-blind trial of prophylaxis against jaundice among breastfed newborns”. [*Pediatrics*. Aug 2005; 116(2):385-91].
62. Grunebaum E, Amir J, Merlob P, et al. “Breast mild jaundice: natural history, familial incidence and late neurodevelopmental outcome of the infant”. *Euro J Pediatr*. Feb 1991; 150(4):267-70.
63. Gruslin-giroux A, Moore TR. “Erythroblastosis Fetalis”. In: Fanaroff AA, Martin RJ. *Neonatal-Perinatal Medicine*. Vol 1. 8th edition. St. Louis, MO: Mosby-year book Inc; 2006:389-408
64. Hammerman C.: “Recent developments in the management of neonatal hyperbilirubinemia”. *NeoReviews* 1. e19-e24.2000
65. Hansen TW. “Acute management of extreme neonatal jaundice--the potential benefits of intensified phototherapy and interruption of enterohepatic bilirubin circulation”. [*Acta Paediatr*. Aug 1997; 86(8):843-6].
66. Haque KM, Rahman M. “An Unusual Case of ABO-Haemolytic Disease of the Newborn”: *Bangladesh Medical Research Council Bulletin* 2000; 26(2): 61-4.



REFERENCES

- 67.Hart C, Cameron R. “The importance of irradiance and area in neonatal phototherapy”. [Arch Dis Child Fetal Neonatal Ed. 2005;90:F437-F440]
- 68.Haslem RHA, Kenna M. “Brainstem Auditory Evoked Potential (BAEP)”. In: Behrman RE, Kliegman RM, and Jenson HB, editors. Nelson Textbook of Pediatrics. W.B. Saunders Company; 2000.
- 69.Hayashi S, Takamiya R, Yamaguchi T et al.” Induction of heme oxygenase-1 suppresses venular leukocyte adhesion elicited by oxidative stress: role of bilirubin generated by the enzyme”.Circ Res; 1999 85,663–671.
- 70.Herold TJ, Whittaker DS, Glynn T. “Determining the accuracy of a rapid point-of-care test for determining Rh(D) phenotype”: *Acad Emerg Med*. May 2005; 12(5):474-6.
- 71.Hertzberg V, Mei J, Therrell BL. “Effect of laboratory practices on the incidence rate of congenital hypothyroidism”: *Pediatrics* May 2010; 125 Suppl 2:S48-53].
- 72.Horn AR, Kirsten GF, Kroon SM, Henning PA, Moller G, Pieper C et al. “Phototherapy and exchange transfusion for neonatal hyperbilirubinaemia”. [SAMJ 2006; 96(9):819-824].
- 73.Higgs DR, Weatherall DJ. “The alpha thalassaemias”: [Cell Mol Life Sci. Apr 2009; 66(7):1154-62].



REFERENCES

- 74.Hsieh TY, Shiu TY, Huang SM, Lin HH, Lee TC, and Chen PJ, et al. "Molecular pathogenesis of Gilbert's syndrome: decreased TATA-binding protein binding affinity of UGT1A1 gene promoter". *Pharmacogenet Genomics*. Apr 2007; 17(4):229-36.
- 75.Hua L, Shi D, Bishop PR, Gosche J, May WL, Nowicki MJ. "The role of UGT1A1*28 mutation in jaundiced infants with hypertrophic pyloric stenosis". [*Pediatr Res*. Nov 2005; 58(5):881-4].
- 76.Huang CS, Chang PF, Huang MJ, Chen ES, Hung KL, Tsou KI. "Relationship between bilirubin UDP-glucuronosyl transferase 1A1 gene and neonatal hyperbilirubinemia": *Pediatr Res*. Oct 2002; 52(4):601-5.
- 77.Huang MJ, Kua KE, Teng HC, Tang KS, Weng HW, Huang CS. "Risk factors for severe hyperbilirubinemia in neonates": *Pediatr Res*. Nov 2004; 56(5):682-9.
- 78.Huang CS, Huang MJ, Lin MS, Yang SS, Teng HC, Tang KS. "Genetic factors related to unconjugated hyperbilirubinemia amongst adults": *Pharmacogenet Genomics*. Jan 2005; 15(1):43-50].
- 79.Institut of Medicine. "Crossing the Quality Chasm": [A New Health System for the 21st Century. Washington, DC: National Academy Press; 2001].
- 80.Ip S, Glicken S, Kulig J, Obrien R, Sege R, Lau J. "Management of Neonatal Hyperbilirubinemia". Rockville, MD: US Department of Health



REFERENCES

- and Human Services, Agency for Healthcare Research and Quality; 2003. AHRQ Publication 03-E011
81. Ip S, Chung M, Kulig J. et al. "An evidence-based review of important issues concerning neonatal hyperbilirubinemia". [Pediatrics. 2004; 113 (6)].
82. Ishizawa S, Yoshida T, Kikuchi G. "Induction of hemeoxygenase in rat liver": J Biol Chem (1983) 258, 4220–4225.
83. Jansen PL. "Diagnosis and management of Crigler-Najjar syndrome": Eur J Pediatr. Dec 1999; 158 Suppl 2:S89-94.
84. Jendrzeczak B, Doumas BT. "Bovine serum–based bilirubin calibrators are inappropriate for some diazo methods". [Clin Chem 2010 56: 869–872].
85. Jeon H, Calhoun B, Pothiwala M, Herschel M, Baron BW. "Significant ABO Hemolytic Disease of the Newborn in a Group B Infant with a Group A2 Mother": Immunohematology 2000; 16(3):105-8.
86. Johnson LH, Bhutani VK, Brown AK." System-based approach to management of neonatal jaundice and prevention of kernicterus": J Pediatr. [Apr 2002; 140(4):396-403].
87. Johnson L, Bhutani VK, Karp K, Sivieri EM, Shapiro SM. "Clinical report from the pilot USA Kernicterus Registry (1992 to 2004)." J Perinatol. Feb 2009; 29 Suppl 1:S25-45



REFERENCES

88. Juetschke, L.J. (2005, Mar/Apr). "Kernicterus: still a concern" [Neonatal Network, 24(2), 7-19, 59-62].
89. Kaplan M, Hammerman C, Vreman HJ, Stevenson DK, Beutler E. "Acute hemolysis and severe neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient heterozygotes": [J Pediatr. Jul 2001; 139(1):137-40].
90. Kaplan M, Hammerman C. "Glucose-6-phosphate dehydrogenase deficiency: a hidden risk for kernicteru": [Semin Perinatol. Oct 2004; 28(5):356-64].
91. Kaplan M, Kaplan E, Hammerman C, Algur N, Bromiker R, Schimmel MS, Eidelman AI. "Rebound bilirubin levels in infants receiving phototherapy" [Arch Dis Child. 2006 Jan; 91(1):31-4. Epub 2005 Oct 13]
92. Kedar PS, Warang P, Colah RB, Mohanty D. "Red cell pyruvate kinase deficiency in neonatal jaundice cases in India": [Indian J Pediatr. Nov 2006; 73(11):985-8].
93. Keren R, Luan X, Friedman S, Saddlemire S, Cnaan A, Bhutani V. "A comparison of Alternative risk assessment Strategies for Predicting Significant Hyperbilirubinaemia in Term and Near-Term Infants". [Pediatr Maisels JM. ""Neonatal Jaundice. [Pediatr Rev 2006; 27:443-454; 2008; 121:e170-9].



REFERENCES

94. Keren R, Tremont K, Luan X, Cnaan A. "Visual assessment of jaundice in term and late preterm infants": Arch Dis Child Fetal Neonatal Ed. Sep 2009; 94(5):F317-22.
95. Kilani RA, Wetmore J. "Neonatal subgaleal hematoma: presentation and outcome--radiological findings and factors associated with mortality": Am J Perinatol. Jan 2006; 23(1):41-8].
96. King SJ, Boothroyd AE. "Cranial trauma following birth in term infants": Br J Radiol. Feb 1998; 71(842):233-8.
97. Kirk JM. "Neonatal jaundice: a critical review of the role and practice of bilirubin analysis". Ann Clin Biochem. 2008; 45(Pt 5):452-62.
98. Kjartansson S, Hammarlund K, Sedin G. "Insensible water loss from the skin during phototherapy in term and preterm infants". [Acta Paediatr. Oct 1992; 81(10):764-8].
99. Koenig JM. "Evaluation and treatment of erythroblastosis fetalis in the neonat". In: Christensen R, ed. Hematologic Problems of the Neonate. Philadelphia, Pa: WB Saunders; 2000:185-207.
100. Konstantina Gkoltsiou, Meropi Tzoufi, Serena Counsell, Mary Rutherford, and Frances Cowan. Serial brain MRI and ultrasound findings: "Relation to gestational age, bilirubin level, neonatal neurologic status and neurodevelopmental outcome in infants at risk of kernicterus". [Early Human Development. 11 Oct 2008; 84(12), Dec 2008:829-838].



REFERENCES

101. Kumral A, Ozkan H, Duman N, Yesilirmak DC, Islekel H, Ozalp Y. “Breast milk jaundice correlates with high levels of epidermal growth factor”: *Pediatr Res*. Aug 2009; 66(2):218-2.
102. Kramer LI. “Advancement of dermal icterus in the jaundiced newborn”. [*Am J Dis Child* 1969; 118(3):454-8].
103. Lazar L, Litwin A, Merlob P. “Phototherapy for neonatal nonhemolytic hyperbilirubinemia”. [*Clin Pediatr* 1993. 92651–657.657].
104. Leduc L, Farine D, Armson BA, et al. “Stillbirth and bereavement: guidelines for stillbirth investigation”: *J Obstet Gynaecol Can*. Jun 2006; 28(6):540-52.
105. Lee RD, Glader JN, Lukens JN. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. *Wintrobe's. "Clinical Hematology"*: 10th ed. Baltimore, Md: Lippincott Williams & Wilkins; 1999: 1132-42
106. Lee P, Jones G, Seibel MJ. Dua. “Polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: a novel mechanism for hyperserotoninaemia in Gilbert's syndrome mimicking carcinoid syndrome?”: [*Eur J Gastroenterol Hepatol*. Apr 2007; 19(4):337-40].
107. Levene MI, Tudehope DI, Sinha S. “Jaundice”. In: [*Essential Neonatal Medicine*. 4th ed. Australia: Blackwell Publishing; 2008. p. 130-141].



REFERENCES

108. Lin Z, Fontaine J, Watchko JF. “Coexpression of gene polymorphisms involved in bilirubin production and metabolism”: *Pediatrics*. Jul 2008; 122(1):e156-62.
109. Linn S, Schoenbaum SC, Monson RR, Rosner B, Stubblefield PG, Ryan KJ. “Epidemiology of neonatal hyperbilirubinemia”: *Pediatrics*. Apr 1985; 75(4):770-4. MacMahon JR, Stevenson DK, Oski FA. “Physiologic jaundice”. In: Taeusch, Ballards, eds. [Avery's Disease of the Newborn. 7th ed. Philadelphia, PA: Saunders; 1998:1003-7].
110. Madan JC, Kendrick D, Hagadorn JI, Frantz ID 3rd. “Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome”. [*Pediatrics*. Feb 2009; 123(2):674-81].
111. Maisels MJ, Gifford K.”Normal serum bilirubin levels in the newborn”. [*Pediatrics*. Nov 1986; 78(5):837-43].
112. Maisels MJ. “Jaundice: In: Avery, Fletcher, eds. “Neonatology, Pathophysiology and Management of the Newborn”. [5th ed. Philadelphia, PA: Lippincott; 1999:765-819].
113. Maisels M J. The clinical approach to the jaundiced newborn. In: Maisels MJ, Watchko JF, eds. Neonatal jaundice. [Amsterdam: Harwood Academic Publishers, 2000. 139–168.16].
114. Maisels MJ, Kring E. “Rebound in serum bilirubin level following intensive phototherapy”. [*Arch Pediatr Adolesc Med* 2002; 156: 669-672]



REFERENCES

115. Maisels MJ, Watchko JF. "Treatment of jaundice in low birthweight infants". [Arch Dis Child Fetal Neonatal Ed 2003; 88:F459-F463].
116. Maisels MJ, McDonagh AF. Phototherapy for Neonatal Jaundice. [N Engl J Med 2008; 358(9):920-928].
117. Maisels MJ, Deridder JM, Kring EA, Balasubramaniam M. Routine transcutaneous bilirubin measurements combined with clinical risk factors improve the prediction of subsequent hyperbilirubinemia": J Perinatol. Sep 2009; 29(9):612-7.
118. Manning D, Todd P, Maxwell M, Jane Platt M. "Prospective surveillance study of severe hyperbilirubinaemia in the newborn in the UK and Ireland": Arch Dis Child Fetal Neonatal Ed. Sep 2007; 92(5):F342-6.
119. Martin CR, Cloherty JP. "Neonatal Hyperbilirubinemia". In: Cloherty JP, Eichenwald EC, Stark AR. [Manual of Neonatal Care. 5th Edition. Philadelphia: Lippincott Williams and Wilkins; 2004:181-212].
120. Maruo Y, Nishizawa K, Sato H, Sawa H, Shimada M. "Prolonged unconjugated hyperbilirubinemia associated with breast milk and mutations of the bilirubin uridine diphosphate-glucuronosyl transferase gene": Pediatrics. Nov 2000; 106(5):E59.
121. McDade J, Abramova T, Mortier N, Howard T, Ware RE. "A novel G6PD mutation leading to chronic hemolytic anemia": [Pediatr Blood Cancer. Dec 2008; 51(6):816-9].



REFERENCES

122. McGrath M, Lepine J, Lee IM, et al. "Genetic variations in UGT1A1 and UGT2B7 and endometrial cancer risk". *Pharmacogenet Genomics*. Mar 2009; 19(3):239-43.
123. Mills JF, Tudehope D. "Fibreoptic phototherapy for neonatal jaundice". [Cochrane Library 2001] Mishra S, Chawla D, Agarwal R, Deorari AK, Paul VK, Bhutani VK. "Transcutaneous bilirubinometry reduces the need for blood sampling in neonates with visible jaundice": *Acta Paediatr*. Dec 2009; 98(12):1916
124. Miranda PS, Bosma PJ. "Towards liver-directed gene therapy for Crigler-Najjar syndrome". [Curr Gene Ther. Apr 2009; 9(2):72-82]. Moise KJ Jr. "Red blood cell alloimmunization in Pregnancy". *Seminars in Hematology*. 2005; 42:169-178
125. Moczygemba CK, Paramsothy P, Meikle S, et al. "Route of delivery and neonatal birth trauma": *Am J Obstet Gynecol*. Jan 13 2010.
126. Moise KJ. "Hemolytic disease of the fetus and newborn." In: Creasy RK, Resnik R: *Maternal-fetal Medicine: Principles and Practice*. 6th edition. Philadelphia: WB Saunders; 2008:477-503.
127. Moise KJ Jr. "Management of rhesus alloimmunization in pregnancy": *Obstet Gynecol*. Jul 2008; 112(1):164-76.
128. Moore LG, Newberry MA, Freeby GM, Crnic LS. "Increased incidence of neonatal hyperbilirubinemia at 3,100 m in Colorado": *Am J Dis Child*. Feb 1984; 138(2):157-61.



REFERENCES

129. Moyer VA, Ahn C, Sneed S. “Accuracy of clinical judgment in neonatal jaundice”. [Arch Pediatr Adolesc Med. 2000; 154:391 –39].
130. Mukherjee S. “Gilbert syndrome, eMedicine”: Nov 2009.
131. Muncie HL Jr, Campbell J. “Alpha and beta thalassemia”: [Am Fam Physician. Aug 15 2009; 80(4):339-44].
132. Murray NA, Roberts IA. “Haemolytic disease of the newborn”: Arch Dis Child Fetal Neonatal Ed. Mar 2007; 92(2):F83-8.
133. National Academy of Clinical Biochemistry. Laboratory Medicine Practice Guidelines. “Evidence-based practice for point-of-care testing. [AACC Press, 2007. Chapter 2. Pages 5–12].
134. Nathan DG, Oski FA. “Hematology of Infancy and Childhood”: [5thed. Philadelphia, Pa: WB Saunders Co; 1998].
135. Newman T B, Escobar G J, Gonzales V M. et al. “Frequency of neonatal bilirubin testing and hyperbilirubinemia in a large health maintenance organization”. [Pediatrics. 1999 Nov; 104(5 Pt 2):1198–203].
136. Newman TB, Kuzniewicz MW, Liljestrand P, Wi S, McCulloch C, Escobar GJ.” Numbers needed to treat with phototherapy according to American Academy of Pediatrics guidelines”: Pediatrics. May 2009; 123(5):1352-9.



REFERENCES

137. Nkhoma ET, Poole C, Vannappagari V, et al. "The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis". *Blood Cells Mol Dis*. May-Jun 2009; 42(3):267-78.
138. Nowicki MJ, Poley JR. "The hereditary hyperbilirubinaemias. Baillieres Clin Gastroenterol.": Jun 1998; 12(2):355-67].
139. Ostanek B, Furlan D, Mavec T, Lukac-Bajalo J. "UGT1A1 (TA) n promoter polymorphism--a new case of a (TA) 8 allele in Caucasians": *Blood Cells Mol Dis*. Mar-Apr 2007; 38(2):78-82.
140. Owens IS, Basu NK, Banerjee R. "UDP-glucuronosyltransferases: gene structures of UGT1 and UGT2 families". *Methods Enzymol*. 2005; 400:1-22.
141. Ozbay Hosnut F, Ozcay F, et al. "Etiology of hemolysis in two patients with hepatitis A infection: glucose-6-phosphate dehydrogenase deficiency or autoimmune hemolytic anemia": [*Eur J Pediatr*. Dec 2008; 167(12):1435-9].
142. Peters AL, Van Noorden CJ. "Glucose-6-phosphate Dehydrogenase Deficiency and Malaria": *Cytochemical Detection of Heterozygous G6PD Deficiency in Women*. *J Histochem Cytochem*. Jun 22 2009].
143. Petit FM, Gajdos V, Francoual J, Capel L, Parisot F, Poüs C, Labrune P. "Allelic heterogeneity of Crigler-Najjar type I syndrome". [*Clin Genet*. Dec 2004; 66(6):571-2].



REFERENCES

144. Perrotta S, Gallagher PG, Mohandas N. “Hereditary spherocytosis”: [Oct 18; 2008; 372(9647):1411-26].
145. Petit FM, Hebert M, Gajdos V, Mollet-Boudjemline A, Labrune P. “Comments on seven novel mutations of the UGT1A1 gene in patients with unconjugated hyperbilirubinemia by D'Apolito et al. [Haematologica. Jul 2007; 92(7):e80].
146. Porter ML, Dennis MC. “Hyperbilirubinemia in the term newborn”. Am Fam Physician 2002].
147. Queensland Government. “Policy Statement and Guidelines. Safe Infant Care to reduce the Risk of Sudden Unexpected Deaths in Infancy”. 2008.
148. Riskin A, Tamir A, Kugelman A, Hemo M, Bader D. “Is visual assessment of jaundice reliable as a screening tool to detect significant neonatal hyperbilirubinemia?” *J Pediatr*. Jun 2008; 152(6):782-7, 787.e12.
149. Report 2002-2003. “National Neonatal Perinatal Database Network”. [New Delhi: National Neonatology Forum of India; 2004].
150. Robert Kliegman , Karen Marc Dante, Hal Jenson, Richard Behrman. [Nelson Essential of pediatrics (2006);Vol 1:316] .
151. Rosa Manganaro, Lucia Marseglia, Carmelo Mami, Giuseppe Saitta, Romana Gargano, Marina Gernellie. “Serum alpha-fetoprotein (AFP) levels in breastfed infants with prolonged indirect hyperbilirubinemia”. *Early Human Development*. 2008; 84:487-490.



REFERENCES

152. Saeki M, Saito Y, Sai K, et al. "A combinatorial haplotype of the UDP-glucuronosyltransferase 1A1 gene (#60-#IB) increases total bilirubin concentrations in Japanese volunteers." *Clin Chem*. Feb 2007; 53(2):356-8.
153. Sackey K. "Hemolytic anemia: Part 2." [Pediatr Rev. Jun 1999; 20(6):204-8].
154. Sackey K. "Hemolytic anemia": Part 1. *Pediatr Rev*. May 1999; 20(5):152-8; quiz 159.
155. Sarkar S, Bhagat I, DeCristofaro JD. "A study of the role of multiple site blood cultures in the evaluation of neonatal sepsis". *J Perinatol*. Jan 1 2006; 26(1):18-22.
156. Sarici SU, Serdar MA, Korkmaz A, et al. "Incidence, course, and prediction of hyperbilirubinemia in near-term and term newborns": *Pediatrics*. 2004; 113:775-80.
157. Schrier SL, Price EA, Powers A, Silberstein LE. "Extrinsic nonimmune hemolytic anemias". In: Hoffman R, Benz EJ Jr., Shattil SS, et al., eds. [Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Churchill Livingstone Elsevier; 2008: chap 48].
158. Schwartz RS. "Autoimmune and intravascular hemolytic anemia"s. In: Goldman L, Ausiello D, eds. [Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007: chap 164].



REFERENCES

159. Seidman DS, Moise J, Ergaz Z. “A new blue light-emitting phototherapy device: A prospective randomized controlled study”. [J Pediatr 2000; 136:771-774].
160. Servedio V, d'Apolito M, Maiorano N, Minuti B, Torricelli F, Ronchi F, et al. Spectrum of UGT1A1 mutations in Crigler-Najjar (CN) syndrome patients: identification of twelve novel alleles and genotype-phenotype correlation. [Hum Mutat. Mar 2005; 25(3):325].
161. Sgro M, Campbell D, Shah V. “Incidence and causes of severe neonatal hyperbilirubinemia in Canada”. [CMAJ. Sep 12 2006; 175(6):587-90].
162. Shapiro SM. “Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND)”: J Perinatol. Jan 2005; 25(1):54-9].
163. Shinwell ES, Sciaky V, Karplus M. “Effect of position changing on bilirubin levels during phototherapy”. [J Perinatol 2002; 22:226-229].
164. Short MA. “Guide to a systematic physical assessment in the infant with suspected infection and/or sepsis”: Adv Neonatal Care. Jun 2004; 4(3):141-53; quiz 154-7.
165. Shapiro SM, Bhutani VK, Johnson L. “Hyperbilirubinemia and kernicterus”: Clinics in Perinatology 2006; 33(2):387-410.
166. Shibahara S., Müller R. M., Taguchi H., and Yoshida T, “Bilirubin Metabolism”, [J Biol Chem (1985) 258, 4220–4225].



REFERENCES

167. Sideman DS, Moise J, Ergaz Z. "A prospective randomized controlled study of phototherapy using blue and blue-green light-emitting devices, and conventional halogen-quartz phototherapy". [J Perinatol 2003; 23:123-127].
168. Sideman DS, Moise J, Ergaz Z. "A new blue light-emitting phototherapy device": A prospective randomized controlled study. [J Pediatr 2000; 136:771-774].
169. Sklar GE. "Hemolysis as a potential complication of acetaminophen overdose in a patient with glucose-6-phosphate dehydrogenase deficiency": [Pharmacotherapy. May 2002 Volume 22, Number 12].
170. Smith JR, Donze A, Schuller L. "An evidence-based review of hyperbilirubinemia in the late preterm infant, with implications for practice management, follow-up, and breastfeeding support": Neonatal Netw. Nov-Dec 2007; 26(6):395-405.
171. Smitherman H, Stark AR, Bhutan VK. "Early recognition of neonatal hyperbilirubinemia and its emergent management". Semin Fetal Neonatal Med. Jun 2006; 11(3):214-24.
172. Slusher TM, Vreman HJ, McLaren DW, Lewison LJ, Brown AK, Stevenson DK. "Glucose-6-phosphate dehydrogenase deficiency and carboxyhemoglobin concentrations associated with bilirubin-related morbidity and death in Nigerian infants": J Pediatr. Jan 1995; 126(1):102-8.



REFERENCES

173. Sneitz N, Bakker CT, de Knecht RJ, et al. "Crigler-Najjar syndrome in The Netherlands: identification of four novel UGT1A1 alleles, genotype-phenotype correlation, and functional analysis of 10 missense mutants": *Hum Mutat.* Jan 2010; 31(1):52-9.
174. Sorantin E, Brader P, Thimary F. "Neonatal trauma." *Eur J Radiol.* Nov 2006; 60(2):199-207].
175. Steven K. Herrine." Merck Manual Jaundice Last full review/revision: July; 2009.
176. Stoehr GA, Stauffer UG, Eber SW. "Near-total splenectomy: a new technique for the management of hereditary spherocytosis": [*Ann Surg.* Jan 2005; 241(1):40-7].
177. Stokowski LA (December 2006). "Fundamentals of phototherapy for neonatal jaundice". [*Adv Neonatal Care* 6 (6): 303–12].
178. Suresh GK, Clark RE. "Cost-effectiveness of strategies that are intended to prevent kernicterus in newborn infant": *Pediatrics.* Oct 2004; 114(4):917-24.
179. Tan KL. "Decreased response to phototherapy for neonatal jaundice in breast-fed infants". [*Arch Pediatr Adolesc Med* 1998; 152:1187-1190].
180. Tan-Dy C, Moore A, Satodia P, et al. "Predicting kernicterus in severe unconjugated hyperbilirubinemia": *Paediatr Child Health* 2004; 9.



REFERENCES

181. Truman P. “Jaundice in the preterm infant: effective management”. [Journal of Neonatal Nursing 2002; 9(1):22-26].
182. Tsezou A, Tzetis M, Giannatou E, et al. “Gilbert syndrome as a predisposing factor for cholelithiasis risk in the Greek adult population”: *Genet Test Mol Biomarkers*. Feb 2009; 13(1):143-6.
183. Urawa N, Kobayashi Y, Araki J, Sugimoto R, Iwasa M, Kaito M. “Linkage disequilibrium of UGT1A1 *6 and UGT1A1 *28 in relation to UGT1A6 and UGT1A7 polymorphisms”. *Oncol Rep*. Oct 2006; 16(4):801-6.
184. Uhing MR. “Management of birth injuries”: *Clin Perinatol*. Mar 2005; 32(1):19-38].
185. Valaes T, Drummond GS, Kappas A. “Control of hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient newborns using an inhibitor of bilirubin production, Sn-mesoporphyrin”: [Pediatrics. May 1998; 101(5):E1].
186. Van der Schoot CE, Tax GH, Rijnders RJ, et al. “Prenatal typing of Rh and Kell blood group system antigens”: the edge of a watershed. *Transfus Med Rev*. Jan 2003; 17(1):31-44.
187. Volpe JJ. Bilirubin and Brain Injury: Neurology of the Newborn.[3rd ed. Philadelphia, PA: WB Saunders; 1995:490-514].
188. Vreman HJ, Wong RJ, Stevenson DK. “Light-emitting diodes: A novel light source for phototherapy”. [Pediatr Res 1998; 44:804-809].



REFERENCES

189. Wang P, Kim RB, Roy-Chowdhury J et al.” Organic anion transport protein SLC21A6 (OATP2) is not sufficient for bilirubin transport.” *J Biol Chem* 2003; 278 (23), 20695–20696.
190. Wang, M, Hays T, Ambruso, DR, Silliman CC, Dickey WC. “Hemolytic Disease of the Newborn Caused by a High Titer Anti-Group B IgG From a Group A Mother”: *Pediatric Blood & Cancer* 2005; 45(6): 861-862.
191. Watchko JF. “Genetics and the risk of neonatal hyperbilirubinemia: commentary on the article by Huang et al. on page 682”: *Pediatr Res*. Nov 2004; 56(5):677-8.
192. Watchko JF. “Kernicterus and the molecular mechanisms of bilirubin-induced CNS injury in newborns.” *Neuromolecular Med*. 2006;8(4):513-29.
193. Watchko JF (). "Hyperbilirubinemia and bilirubin toxicity in the late preterm infant". [*Clin Perinatol*; December 2006; 33 (4): 839–52.
194. Watchko JF: “Identification of neonates at risk for hazardous hyperbilirubinemia”: emerging clinical insights. *Pediatr Clin North Am*; 2009 Jun; 56(3):671-87.
195. Watson RL.”Hyperbilirubinemia”. *Crit Care Nurs Clin North Am*. 2009 Mar; 21(1):97-120, vii]
196. Wentworth, Stephanie D.P. “Neonatal Phototherapy – today’s lights, lamps and devices”: *Infant*. 2005: Volume 1 Issue 3: 14 – 19.



REFERENCES

197. Yamamoto A, Nishio H, Waku S, Yokoyama N, Yonetani M, Uetani Y. "Gly71Arg mutation of the bilirubin UDP-glucuronosyltransferase 1A1 gene is associated with neonatal hyperbilirubinemia in the Japanese population": J Med Sci. Aug 2002; 48(3-4):73-7].
198. Yusoff S, Van Rostenberghe H, Yusoff NM, Talib NA, Ramli N, Ismail NZ. "Frequencies of A (TA) 7TAA, G71R, and G493R mutations of the UGT1A1 gene in the Malaysian population": Biol Neonate. 2006; 89(3):171-6.
199. Zanardo V, Golin R, Amato M, Trevisanuto D, Favaro F, Faggian D. "Cytokines in human colostrum and neonatal jaundice": Pediatr Res. Aug 2007; 62(2):191-4.
200. Zecca E, Barone G, De Luca D, Marra R, Tiberi E, Romagnoli C. "Skin bilirubin measurement during phototherapy in preterm and term newborn infants". [Early Hum Dev. 2009; 85(8):537-40].
201. Zuckerman K. Approach to the anemias.[In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007: chap 162].
202. Zung A, Tenenbaum-Rakover Y, Barkan S, Hanukoglu A, HersHKovitz E, Pinhas-Hamiel O. "Neonatal hyperthyrotropinemia: population characteristics, diagnosis, management and outcome after cessation of therapy": [Clin Endocrinol (Oxf). May 18 2009].